Nothing Special   »   [go: up one dir, main page]

CY1105706T1 - Υγρο σκευασμα που περιεχει ολιγοπεπτιδια και αιθεροποιημενη κυκλοδεξτρινη - Google Patents

Υγρο σκευασμα που περιεχει ολιγοπεπτιδια και αιθεροποιημενη κυκλοδεξτρινη

Info

Publication number
CY1105706T1
CY1105706T1 CY20061101478T CY061101478T CY1105706T1 CY 1105706 T1 CY1105706 T1 CY 1105706T1 CY 20061101478 T CY20061101478 T CY 20061101478T CY 061101478 T CY061101478 T CY 061101478T CY 1105706 T1 CY1105706 T1 CY 1105706T1
Authority
CY
Cyprus
Prior art keywords
cyclodextrin
etherophydated
liquid preparation
preparation containing
containing oligopeptides
Prior art date
Application number
CY20061101478T
Other languages
English (en)
Inventor
Hiltrud Lindenblatt
Hans-Peter Zobel
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CY1105706T1 publication Critical patent/CY1105706T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η προκειμένη εφεύρεση αφορά σε ένα υδατικό φαρμακευτικό σκεύασμα ολιγοπεπτιδίων, που περιέχει ένα ολιγοπεπτίδιο του τύπου I, κυκλο-(n-Arg-nGly-nAsp-nD-nE) και μία μερικώς αιθεροποιημένη β-κυκλοδεξτρίνη με μία διαλυτότητα στο ύδωρ μεγαλύτερη από 1,8 mg ανά ml ύδατος, ως και στην παρασκευή του υδατικού φαρμακευτικού σκευάσματος.
CY20061101478T 2002-06-24 2006-10-16 Υγρο σκευασμα που περιεχει ολιγοπεπτιδια και αιθεροποιημενη κυκλοδεξτρινη CY1105706T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10228049A DE10228049A1 (de) 2002-06-24 2002-06-24 Flüssige Zubereitung enthaltend Oligopeptide
PCT/EP2003/005224 WO2004000344A1 (de) 2002-06-24 2003-05-19 Flüssige zubereitung enthaltend oligopeptide und verethertes cyclodextrin

Publications (1)

Publication Number Publication Date
CY1105706T1 true CY1105706T1 (el) 2010-12-22

Family

ID=29723395

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101478T CY1105706T1 (el) 2002-06-24 2006-10-16 Υγρο σκευασμα που περιεχει ολιγοπεπτιδια και αιθεροποιημενη κυκλοδεξτρινη

Country Status (22)

Country Link
US (1) US7262165B2 (el)
EP (1) EP1515740B1 (el)
JP (1) JP5052750B2 (el)
KR (1) KR101024511B1 (el)
CN (1) CN100368013C (el)
AR (1) AR040444A1 (el)
AT (1) ATE337013T1 (el)
AU (1) AU2003240268B2 (el)
BR (1) BR0312157A (el)
CA (1) CA2490735C (el)
CY (1) CY1105706T1 (el)
DE (2) DE10228049A1 (el)
DK (1) DK1515740T3 (el)
ES (1) ES2270042T3 (el)
HK (1) HK1079430A1 (el)
MX (1) MXPA04012426A (el)
MY (1) MY135548A (el)
PL (1) PL205972B1 (el)
PT (1) PT1515740E (el)
RU (1) RU2322254C2 (el)
WO (1) WO2004000344A1 (el)
ZA (1) ZA200500585B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034099T2 (en) 2004-01-30 2018-01-29 Zoetis Services Llc Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
DK2047857T3 (da) * 2006-06-29 2012-02-27 Arigen Pharmaceuticals Inc Middel til injektionsformål omfattende antibiotika og opløsning til injektion omfattende midlet
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
DK2101805T3 (da) * 2007-01-18 2013-01-21 Merck Patent Gmbh Integrinligander til anvendelse i behandling af cancer
WO2009110880A1 (en) * 2008-03-01 2009-09-11 Hewlett-Packard Development Company, L.P. Detecting colorants within carrier liquid
PE20120169A1 (es) * 2008-11-17 2012-02-29 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
EP2370070B9 (en) 2008-11-25 2014-04-23 Boehringer Ingelheim Vetmedica GmbH Pimobendan for use in the treatment of hypertrophic cardiomyopathy in cats.
EA022700B1 (ru) * 2009-12-10 2016-02-29 Мерк Патент Гмбх Фармацевтическая композиция, содержащая олигопептиды
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
CN105377235A (zh) 2013-07-19 2016-03-02 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
HUE056143T2 (hu) 2013-12-04 2024-01-28 Boehringer Ingelheim Vetmedica Gmbh Pimobendán javított gyógyászati készítményei
WO2017117311A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Formulations with reduced degradation of polysorbate
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
CA3083190A1 (en) * 2017-11-30 2019-06-06 Cytogel Pharma, Llc Novel analgesic pharmaceutical formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
EA200101088A1 (ru) * 1999-04-15 2002-04-25 Эли Лилли Энд Компани Противогрибковые композиции псевдомицинов и способы их применения

Also Published As

Publication number Publication date
ES2270042T3 (es) 2007-04-01
US7262165B2 (en) 2007-08-28
WO2004000344A1 (de) 2003-12-31
ATE337013T1 (de) 2006-09-15
CN1662250A (zh) 2005-08-31
AR040444A1 (es) 2005-04-06
PL372192A1 (en) 2005-07-11
KR101024511B1 (ko) 2011-03-31
DE50304763D1 (de) 2006-10-05
EP1515740A1 (de) 2005-03-23
CA2490735C (en) 2012-11-20
RU2322254C2 (ru) 2008-04-20
DE10228049A1 (de) 2004-01-15
JP5052750B2 (ja) 2012-10-17
EP1515740B1 (de) 2006-08-23
RU2005101746A (ru) 2005-08-27
MXPA04012426A (es) 2005-04-19
PT1515740E (pt) 2007-01-31
DK1515740T3 (da) 2006-12-11
ZA200500585B (en) 2005-11-30
KR20050013612A (ko) 2005-02-04
US20050239692A1 (en) 2005-10-27
MY135548A (en) 2008-05-30
PL205972B1 (pl) 2010-06-30
CA2490735A1 (en) 2003-12-31
AU2003240268B2 (en) 2008-10-23
HK1079430A1 (en) 2006-04-07
JP2005534671A (ja) 2005-11-17
BR0312157A (pt) 2005-03-29
AU2003240268A1 (en) 2004-01-06
CN100368013C (zh) 2008-02-13

Similar Documents

Publication Publication Date Title
CY1105706T1 (el) Υγρο σκευασμα που περιεχει ολιγοπεπτιδια και αιθεροποιημενη κυκλοδεξτρινη
CY1112527T1 (el) Συνθεσεις που περιεχουν αμιοdαrονε και sulfoalkyl ether cyclodextrin
CY1116023T1 (el) Μορφες φαρμακευτικης δοσολογιας παρατεταμενης απελευθερωσης με περιγραμματα διαλυτοποιησης ελαχιστοποιημενης εξαρτησης απο το ph
UY27575A1 (es) Soluciones de metolixicam estables y muy concentradas para la inyección sin aguja
PE84899A1 (es) Formulaciones farmaceuticas que contienen voriconazol
PT1299107E (pt) Solucoes estaveis muito concentradas de meloxicam
CY1105690T1 (el) Μεθοδοι και σκευασματα για χορηγηση ταξανιων
CY1107294T1 (el) Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες
PE20060880A1 (es) Conjugados de polipeptido y un pentasacarido que tienen propiedades farmacocineticas mejoradas
EA199900979A1 (ru) Композиции активированного протеина
ATE396745T1 (de) Complex enthaltend modafinil und cyclodextrin
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
ATE422356T1 (de) Pharmazeutische zubereitungen
IS5851A (is) Ný lyf til inntöku 5-HT4 gerandefna eða mótlyfja
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
AR024959A1 (es) Una composicion farmaceutica liquida basada en paracetamol
CY1107825T1 (el) Εισπνεομενα σκευασματα τυπου διαλυματος με αλαστιοτροπιου
BR9805875A (pt) Composições farmacêuticas de droloxifeno.
ATE388960T1 (de) Glykopeptidderivate mit carboxysacchariden
CO5640149A2 (es) Formulaciones parenterales de un peptido para el tratamiento de lupus sistematico eritematoso
ATE317695T1 (de) Parenterale lösung enthaltend amiodaron
PT1729813E (pt) Complexos de inclusão obtidos utilizando um processo com co2 supercrítico e um agente de interacção com o complexo
HRP20070081T3 (en) Nasal pharmaceutical composition of piribedil
BR0006838A (pt) Complexos de paroxetina, com ciclodextrinas ou derivados de ciclodextrinas
ATE281832T1 (de) Pharmazeutische zusammensetzungen mit antitumoraler wirkung auf basis von carboplatin